Clinical Trial: Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07687875) titled 'Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer' on June 20.

Brief Summary: A Phase I clinical trial that will investigate the safety and tolerability of combining the modified vaccinia virus BT-001 with systemic pembrolizumab in patients with localised pMMR rectal cancer

Study Start Date: June 17

Study Type: INTERVENTIONAL

Condition: Rectal Cancer Patients

Intervention: DRUG: BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody)

Two doses of BT-001 delivered by intra-tumoural injection followed by one systemic dose of pembrolizumab

Recr...